Oncolytics Biotech Inc. (ONCY)

CA — Healthcare Sector
Peers: SCPH  MIST  MCRB  LIFE  DMAC  IKT    XFOR  GRTX  TERN  DAWN  HOOK  CVAC  RETA  KRYS  VIR  PPCB 

Automate Your Wheel Strategy on ONCY

With Tiblio's Option Bot, you can configure your own wheel strategy including ONCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ONCY
  • Rev/Share 0.0
  • Book/Share 0.0786
  • PB 6.0018
  • Debt/Equity 0.1778
  • CurrentRatio 2.8226
  • ROIC -1.9396

 

  • MktCap 41917264.2352
  • FreeCF/Share -0.266
  • PFCF -2.0712
  • PE -1.1324
  • Debt/Assets 0.0527
  • DivYield 0
  • ROE -2.2521

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
ONCY
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral

Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m.

Read More
image for news Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
ONCY
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q4 2024 Results Conference Call March 7, 2025 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chairman of Oncotic's Board of Directors and Interim CEO Tom Heineman - Chief Medical Officer Kirk Look - Chief Financial Officer Christophe Degois - Vice President of Business Development Conference Call Participants Michael Freeman - Raymond James Luis Santos - H.C. Wainwright Operator Good morning, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2024 conference call.

Read More
image for news Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
ONCY
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m.

Read More
image for news Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
ONCY
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors //Republication of press release issued February 18 th 2025 due to news transmission coverage// SAN DIEGO and CALGARY, AB , Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments …

Read More
image for news Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
ONCY
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study …

Read More
image for news Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
ONCY
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on February 13, 2025 indicating that the Company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the Company's ordinary shares listed on the Nasdaq Capital Market was …

Read More
image for news Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

About Oncolytics Biotech Inc. (ONCY)

  • IPO Date 2001-10-05
  • Website https://www.oncolyticsbiotech.com
  • Industry Biotechnology
  • CEO Mr. Wayne F. Pisano M.B.A.
  • Employees 28

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.